Douglas Johnson, MD, and Eric Roselli, MD, staff cardiac surgeons at the Cleveland Clinic’s Miller Family Heart & Vascular Institute, recently performed the first implantations in the U.S. of the Perceval sutureless heart valve.
The FDA approved the Perceval sutureless heart valve on Jan. 8 for patients requiring an aortic valve replacement procedure. The valve has been implanted in more than 15,000 patients in more than 300 hospitals worldwide, according to LivaNova.
The company said that studies have shown patients using the Perceval sutureless heart valve had shorter intensive care unit stays, ventilation time reduction and fewer blood transfusions compared with those using traditional surgical valves. The valve also has lower procedural costs than traditional sutured valves.
Liva Nova, which was formed by the merger of Sorin S.p.A. and Cyberonics, Inc., has approximately 4,500 employees working in three business units: cardiac rhythm management, cardiac surgery and neuromodulation. The company said in a news release that Roselli receives honoria from the company for providing educational programs.